Lv5
1160 积分 2024-03-07 加入
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
1天前
已完结
Changing innovation into a registered product: From concept to regulatory approval
15天前
已关闭
Mechanistic Studies of Glass Vial Breakage for Frozen Formulations. II. Vial Breakage Caused by Amorphous Protein Formulations
2个月前
已完结
Mechanical Characterization of Vial Strain During Freezing and Thawing Operations Using Amorphous Excipients
2个月前
已关闭
Poloxamer 188 as surfactant in biological formulations – An alternative for polysorbate 20/80?
3个月前
已完结
Value of Real-World Evidence for Treatment Selection: A Case Study in Colon Cancer
3个月前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
3个月前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
3个月前
已完结
Benchmarking recruitment rates for phase III trials
3个月前
已完结
Supply Chain Planning for Clinical Trials – A Practical Guide
4个月前
已完结
皖公网安备34019202002308
